Kura Oncology (KURA) 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA summary

Company overview and strategic direction

• KOMZIFTI approved for relapsed/refractory NPM1-mutant AML, with robust early launch momentum and strong new patient starts.

• Advancing ziftomenib as a combinable backbone in AML, with multiple data readouts expected this year.

• Proof-of-concept data positions darlifarnib as a foundational therapy in kidney cancer and KRAS-driven solid tumors.

• Focus on maintaining execution and momentum, with goals of quarter-over-quarter growth and market leadership in NPM1-mutant AML.

• Well-financed to support ongoing clinical and commercial objectives.

Clinical data highlights and development plans

• Adagrasib combination showed high response rates: 50% in late-line NSCLC, 67% in PDAC, and 29% in KRAS inhibitor-naive colorectal cancer.

• Adverse events were consistent with known profiles of individual drugs, with no overlapping toxicity observed.

• Lower doses of darlifarnib (3 mg and 5 mg) selected for further development due to favorable benefit-risk profile.

• Future development will focus on selected tumor types, with more details to be shared at an upcoming investor event.

• Darlifarnib shown to inhibit mTORC1 signaling, potentially preventing resistance and deepening responses in combination therapies.

AML program and trial updates

• KOMET-007 phase I data showed high complete response rates: 94% for NPM1 and 82% for KMT2A, with strong MRD negativity.

• One-year overall survival exceeded historical controls, with 94% for NPM1 and 70% for KMT2A.

• Central bone marrow MRD negativity is more sensitive than plasma, with 45% expected for 7+3 alone.

• Patients have the option for transplant; post-transplant maintenance is being tracked.

• Large phase I enrollment (over 200 patients) supports confidence in pivotal trial reproducibility.